Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 63 clinical trials
AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)

(apixaban) and no oral anticoagulation in patient with sinus rhythm one year after catheter ablation of AF.

  • 0 views
  • 24 Jan, 2021
HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID)

quality of life associated with COVID-19. The first two treatment arms are Apixaban and Atorvastatin, with further treatment arms to be added at the direction of the UK COVID-19 Therapeutic

  • 0 views
  • 02 Aug, 2021
  • 1 location
Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension (APIS)

and TIPSS (transjugular intrahepatic portosystemic shunt) or liver transplantation for severe cases. The investigators hypothesize that anticoagulation using Apixaban in patients with INCPH

  • 0 views
  • 05 Apr, 2022
  • 1 location
Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access

atrial fibrillation. They also replaced oral and parenteral anticoagulants in the treatment and prevention of deep vein thrombosis. Among the 4 available NOACs today, only apixaban had received approval

  • 0 views
  • 25 Jan, 2021
  • 2 locations
DOT HeartMate 3 Study

A prospective, single-center, randomized controlled trial of the feasibility and safety of apixaban in HeartMate 3 patients.

  • 0 views
  • 21 Apr, 2022
  • 1 location
Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm (BOAT OAR)

There is a need to determine actual compliance of direct oral anticoagulants and how to improve this to reduce risk of stroke in patients with atrial fibrillation. Mobile health tools have been implemented world-wide in various patient populations as means of reducing cardiovascular risk and improving disease management. Results of …

  • 4 views
  • 22 Mar, 2022
  • 1 location
Apixaban for Extended Anticoagulation (APIDULCIS) (APIDULCIS)

with Apixaban 2,5 mg x 2 for 18 months as extended treatment. Patients at low risk, with normal D-dimer test, will stop anticoagulation definitely.

thrombosis
venous thromboembolism
pulmonary embolism
deep vein thrombosis
apixaban 2.5 mg
  • 14 views
  • 14 Feb, 2022
  • 1 location
API-CAT STUDY for APIxaban Cancer Associated Thrombosis (API-CAT)

The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent venous

  • 33 views
  • 07 Feb, 2022
  • 64 locations
Apixaban for the Acute Treatment of Venous Thromboembolism in Children

To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.

heparin
venous thromboembolism
anticoagulation therapy
vitamin k
vitamin k antagonist
  • 0 views
  • 05 May, 2022
  • 64 locations
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism (COBRRA)

Apixaban and rivaroxaban have been compared to standard therapy for treatment of acute symptomatic venous thromboembolism (VTE) in randomized controlled trials (RCTs), and are both approved by

venous thromboembolism
rivaroxaban
probe
anticoagulants
apixaban
  • 293 views
  • 31 Jan, 2022
  • 17 locations